AbbVie announced that the FDA has approved a new packaging option for AndroGel (testosterone gel) 1.62%. Besides the previously approved metered-dose pump packaging, Androgel 1.62% will also be ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...

Torrance, Calif. (May 4, 2004) – Long-term use of AndroGel® (testosterone gel 1% CIII) is safe and effective for men with hypogonadism, a condition sometimes referred to as low testosterone, according ...

AndroGel (testosterone gel) is prescribed to treat low testosterone levels. AndroGel’s cost may depend on your dosage and whether you have health insurance. It also may depend on the pharmacy you use ...

Testosterone therapy, in which testosterone is administered to men with low levels of the hormone, has been a controversial topic, with some advocating for the therapy as a way to restore vitality in ...

Interested in elevating your vitality with hormonal supplements? Discover safe and legal Testosterone Gel options for sale in AU. Find top-quality hormone balance solutions, carefully curated to suit ...

Androgel (testosterone) is a brand-name topical gel that’s prescribed for low testosterone due to certain medical conditions in adults. The cost of the drug with and without insurance can depend on ...

Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the U.S. and Mexico will be terminated as of June ...

San Diego, CA-- A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the ...

DUBLIN, March 16, 2015 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO™ ...